Charmaine Semeniuk
Psychiatry · San Diego, CANPI 1215012836
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,682 of the $7,543 with a category attached, or 75.3%. It is spread thinly across 15 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,107 and has fallen 67.0% since, to $696 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $39.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$899
- Otsuka America Pharmaceutical, Inc.$775
- Alkermes, Inc.$698
- Axsome Therapeutics, Inc.$588
- plus $2K from 9 others
Across 703 payments — averaging $12,598 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4.2M
- Teva Pharmaceuticals USA, Inc.$2.1M
- AbbVie$1.3M
- E.r. Squibb & Sons, L.L.C.$411K
- Janssen Research & Development, LLC$183K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$179K
- plus $442K from 10 others
What the payments were for
- Consulting fees$4005%
- Travel & lodging$1,26517%
- Food & beverage$5,68275%
- Education$1963%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 10 | $1,565 |
| Teva Pharmaceuticals USA, Inc. | 45 | $1,191 |
| Neurocrine Biosciences, Inc. | 24 | $899 |
| Otsuka America Pharmaceutical, Inc. | 23 | $775 |
| Alkermes, Inc. | 16 | $698 |
| Axsome Therapeutics, Inc. | 8 | $588 |
| AbbVie(2 entities) | 29 | $574 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $484 |
| Lundbeck LLC | 9 | $149 |
| Sunovion Pharmaceuticals Inc. | 2 | $143 |
| Idorsia Pharmaceuticals US Inc | 1 | $129 |
| Boehringer Ingelheim | 1 | $117 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| Johnson & Johnson | 4 | $94 |
| Acadia Pharmaceuticals Inc | 3 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$982
- LYBALVI$884
- Auvelity$450
- CAPLYTA$343
- ARISTADA INITIO$245
- ABILIFY MAINTENA$242
- AUSTEDO$219
- REXULTI$138
- QUVIVIQ$129
- LATUDA$125
- VRAYLAR$123
- ABILIFY ASIMTUFII$122
- INGREZZA$119
How this compares
$7,543 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrochlorothiazide | 13 | $22 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Diego
- Jonathan MeyerSan Diego$2.3M
- Sanjai RaoSan Diego$445K
- Murray SteinSan Diego$121K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.